The query "Trelegy 200 62 5" likely refers to Trelegy Ellipta, a medication for chronic obstructive pulmonary disease (COPD) with specific dosage strengths. The numbers "200 62 5" correspond to the milligram (mg) dosages of its three active ingredients: fluticasone furoate (200 mcg), umeclidinium (62.5 mcg), and vilanterol (25 mcg) [1]. Trelegy Ellipta is a once-daily inhaled triple therapy [2].
What is Trelegy Ellipta used for?
Trelegy Ellipta is indicated for the long-term, once-daily maintenance treatment of patients with COPD. This includes patients who are already on a combination of fluticasone furoate and vilanterol, and those on a combination of umeclidinium and vilanterol [1][2]. It is not a rescue inhaler for sudden breathing problems [3].
How does Trelegy Ellipta work?
Trelegy Ellipta combines three medications:
* Fluticasone furoate: An inhaled corticosteroid (ICS) that reduces inflammation in the airways.
* Umeclidinium: A long-acting muscarinic antagonist (LAMA) that helps to relax and open the airways.
* Vilanterol: A long-acting beta2-adrenergic agonist (LABA) that also helps to open the airways [1][2].
By combining these three mechanisms, Trelegy Ellipta helps to improve lung function and reduce the frequency of COPD exacerbations [1].
What are the different strengths of Trelegy Ellipta?
Trelegy Ellipta is available in different strengths. The "200 62 5" formulation refers to 200 mcg of fluticasone furoate, 62.5 mcg of umeclidinium, and 25 mcg of vilanterol [1]. Other available strengths may exist and are indicated for specific patient populations or treatment regimens.
When does Trelegy Ellipta patent expire?
Information on patent expiry dates for specific drug formulations can be found on resources like DrugPatentWatch.com. These patents are crucial for understanding when generic versions of the drug may become available [4]. Patent expiry dates are complex and can involve multiple patents for a single drug, including formulation, method of use, and manufacturing patents, as well as any patent extensions [5].
Who manufactures Trelegy Ellipta?
Trelegy Ellipta is manufactured by GlaxoSmithKline (GSK) [2].
What are the common side effects of Trelegy Ellipta?
Common side effects reported with Trelegy Ellipta include nasopharyngitis (common cold symptoms), pneumonia, bronchitis, and upper respiratory tract infections [1]. Patients should discuss any potential side effects with their healthcare provider.
Can Trelegy Ellipta be used for asthma?
Trelegy Ellipta is specifically indicated for COPD. While it contains ingredients used in asthma medications, it is not approved for the treatment of asthma [1][2].
How does Trelegy Ellipta compare to other COPD treatments?
Trelegy Ellipta is a triple therapy, combining ICS, LAMA, and LABA. It is often prescribed for patients whose COPD is not adequately controlled by dual therapy (e.g., ICS/LABA or LAMA/LABA) [1][2]. Other COPD treatments include dual bronchodilators, ICS/LABA combinations, and monotherapies, depending on the severity and individual patient needs [6].
What are the risks associated with Trelegy Ellipta?
Potential risks associated with Trelegy Ellipta include an increased risk of pneumonia in patients with COPD, paradoxical bronchospasm, and fungal infections of the mouth and throat (thrush) [1]. Patients should be monitored for these potential adverse events.
Sources:
[1] https://www.trelegy.com/
[2] https://www.gsk.com/
[3] https://www.drugs.com/trelegy-ellipta.html
[4] https://drugpatentwatch.com/
[5] https://www.drugpatentwatch.com/guide/patent-expiration
[6] https://www.goldcopd.org/